Three-Year Outcomes from BENEFIT, a Randomized, Active-Controlled, Parallel-Group Study in Adult Kidney Transplant Recipients
Flavio Vincenti(University of California, San Francisco), Christian P. Larsen(Emory University), Josefina Alberú(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Barbara A. Bresnahan(Medical College of Wisconsin), Valter Duro Garcı́a(Santa Casa Hospital), J. Kothari(P. D. Hinduja Hospital and Medical Research Centre), Philippe Lang(Université Paris-Est Créteil), Eduardo Mancilla Urrea(Instituto Nacional de Cardiología), P. Massari(Hospital Privado), G. Mondragon-Ramirez, Rafael Reyes‐Acevedo(Universidad Villasunción), Kim Rice(Baylor University Medical Center), Lionel Rostaing(Inserm), S. Steinberg(Sharp Memorial Hospital), J. Xing(Bristol-Myers Squibb (United States)), Mamta Agarwal(Bristol-Myers Squibb (United States)), M. Harler(Bristol-Myers Squibb (United States)), B Charpentier(Université Paris-Sud)
Cited by 308Open Access
Abstract
Related Papers
A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
Flavio Vincenti, B Charpentier, Yves Vanrenterghem et al.|American Journal of Transplantation|2010|941
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
Antoine Dürrbach, JO Medina Pestana, Thomas C. Pearson et al.|American Journal of Transplantation|2010|561
Complete Avoidance of Calcineurin Inhibitors in Renal Transplantation: A Randomized Trial Comparing Sirolimus and Tacrolimus
Timothy S. Larson, Patrick G. Dean, Mark D. Stegall et al.|American Journal of Transplantation|2006|299